Alzheimer’s Death Panels

 

What are “death panels?” The phrase came into popular use with the passage of the Affordable Care Act (ObamaCare) in 2010. One of the provisions of this healthcare legislation was the formation of a medical advisory board, called the Independent Payment Advisory Board (IPAB). IPAB was to be composed of 15 individuals appointed by the President who will be given significant power to cut Medicare spending in the future if there are cost over-runs. In other words, this advisory board would have the power to ration care if they thought it was too costly.

It was former Governor of Alaska and Vice-Presidential candidate Sarah Palin who first referred to this IPAB as a “death panel.” She meant that the decisions of this board could amount to a death sentence if life-saving or prolonging treatments were denied to seniors because they were deemed to be too expensive. This concept of rationing care “for the good of the whole” is a common feature of socialized medicine systems.

While the IPAB was never actually formed, as the ObamaCare legislation planned, the concept of rationing care based on the perceived value to society, rather than the individual, has not died. It is rearing its ugly head once again in the debate over the treatment of Alzheimer’s disease.

In an earlier post called Alzheimer’s Hope Arrives I reported on the Food and Drug Administration (FDA) approval of a new treatment of Alzheimer’s disease called aducanumab or Aduhelm. It is the first drug that has shown significant effectiveness in the removal of the amyloid plague buildup in the brain associated with the disease.

The approval of Aduhelm has been controversial. A randomized controlled clinical trial showed a high-dose of the treatment removed 71% of the amyloid plague buildup after 18 months and significantly slowed disease progression, as rated by care-givers and doctors. Another trial also showed amyloid clearance but failed to demonstrate a significant impact on disease progression.

The Wall Street Journal editorial board says the manufacturer, Biogen, then made a mistake by halting both trials early. But it later worked with the FDA on a post-hoc review to understand the discordant results. One major discrepancy: Patients in the second trial received less treatment. The longer patients in both trials received a high-dose of the drug, the less they deteriorated.

Critics of Aduhelm, largely on the public-health left, claim that the successful trial was likely a false positive since other experimental monoclonal antibody treatments have failed to show an effect on amyloid or disease progression. Some neurologists also believe clearing amyloid is ineffective because Alzheimer’s has other causes.

Despite these criticisms, Aduhelm is the first drug to show a meaningful effect on disease progression in early-stage patients. It has the potential to extend the time that patients can live independently and spend with their loved ones, while researchers work on other therapies that target different disease pathways. The costs associated with Alzheimer’s disease in the U.S. are estimated at $277 billion a year. You would think this alone would be a large incentive to pursue any treatments that might mitigate these costs, let alone relieve some of the suffering of these patients and their families.

Yet the critics have not let up even though the FDA approved the drug. They urged the FDA to require another large clinical trial before granting approval. When they lost this argument, they switched to obstructing payment of treatment by Medicare. They lobbied CMS – the Centers for Medicare and Medicaid Services – to restrict Medicare coverage. Although CMS has almost always covered FDA-approved drugs, they flinched with Aduhelm. Now CMS says Medicare will only pay for Aduhelm, and any future Alzheimer’s amyloid-targeting monoclonal treatments approved by the FDA, if patients enroll in a randomized controlled trial. In other words, CMS is overruling the FDA and doctors who may wish to prescribe these drugs to their patients.

There are other drugs in the development phase that also target amyloid. Three trials of other monoclonal treatments by Eli Lilly, Roche, and Biogen-Eisai have also shown positive results in early trials, some stronger than Aduhelm. But even though these drugs may obtain accelerated approval from the FDA, under CMS’s proposal, Medicare will only pay for them if patients enroll in duplicative trials in which they could be assigned a placebo, instead of the real drug.

Furthermore, it seems the CMS is also pushing for “wokeness” by saying, “the diversity of patients included in each trial must be representative of the national population diagnosed with AD.” WSJ says this is a bow to liberal criticism that the Aduhelm trials included too few blacks, who are twice as likely to develop dementia than whites. Yet these restrictions on trials will only further delay the approval of drugs that would disproportionately benefit blacks.

The real reason for the criticisms of these drugs is cost. Liberals warn Medicare spending will explode if seniors get access to Aduhelm, which costs $28,200 annually. WSJ says, “This is the real reason the Biden Administration wants to pre-emptively restrict Medicare coverage of all amyloid-targeting monoclonals. Progressives want to expand Medicare benefits to win senior votes, then ration treatments to contain government spending. Alzheimer’s drugs won’t be the last rationing target.”

Sounds like death panels by a different name.

Risk Factors for Long Covid

Long Covid was mocked when first reported in 2020. I confess to posting a critical article about a year ago (Fake Science Behind Long Covid Symptoms) that reported on the work of Dr. Jeremy Devine, a psychiatry resident at McMaster University in Hamilton, Ontario. He believed there was no scientific basis for the condition. However, he did say it deserves serious study.

The National Institutes of Health devoted $1.15 billion to research the “prolonged health consequences” of Covid-19 infection. That research may be proving a good investment as new studies are helping advance our understanding of the biology behind long Covid, and providing clues to potential treatment.

Long Covid is characterized by a range of symptoms including fatigue, brain fog, and racing heart rates that persist months after an initial Covid-19 infection. Sumathi Reddy, writing in The Wall Street Journal, says scientists have identified four risk factors for which they tested upon a patient’s initial diagnosis.

  • Autoantibodies
  • Epstein-Barr virus
  • Type 2 diabetes
  • Genetic material of Covid-19 in the blood

 

The first of these risk factors was the presence of certain autoantibodies, which are antibodies that mistakenly attack the body in autoimmune conditions such as lupus. Researchers found the autoantibodies in about 60% of the patients who developed long Covid. Most patients didn’t have a diagnosed autoimmune disease, but rather had very low levels of autoantibodies associated with various autoimmune diseases.

A second risk factor was reactivated Epstein-Barr virus (EBV). EBV is associated with mononucleosis and infects about 90% of people, usually in their teens. Normally, the virus remains dormant afterward, but may become reactivated in some people for various reasons, including those who later developed long Covid.

Dr. Jim Heath, senior author of the study and president and professor of the Institute for Systems Biology in Seattle, says, “Your immune system is probably doing a reasonable job of keeping EBV in check and with a SARS-CoV-2 (Covid-19) infection you lose that brake. It seems to happen very early in an infection.”

Two other risk factors were Type 2 diabetes (adult onset) and the detection of genetic material from SARS-CoV-2 in the blood, which means the virus escaped the lungs and is spreading to other parts of the body. The researchers collected and analyzed blood and swab samples from more than 200 Covid-19 patients up to two to three months post-infection. The majority of patients were hospitalized for Covid, but the tests were replicated on a separate group of roughly 100 patients with mostly mild Covid-19 infections. The tests were also conducted on about 460 healthy people in a control group.

In a separate new study in Nature Communications, researchers in Switzerland found five different factors that they concluded will help predict who will develop long Covid. Those five factors include:

  • Lower levels of two immunoglobulins – IgM and IgG3 (antibodies)
  • Older age
  • History of asthma
  • Symptoms of fever, fatigue, cough, difficulty breathing and G.I. issues during an acute Covid-19 infection (people with long Covid had at least 3 of these)

 

What treatment is available for long Covid?

Identifying treatments for long Covid is the goal of this research. One possibility is treating those with the virus in the blood with one of the new Covid antiviral drugs. Researchers also found that some long Covid patients have very depleted levels of cortisol, resulting in Addison’s disease, which has symptoms such as fatigue and muscle aches. Addison’s patients are often treated with cortisol replacement therapy.

More research is needed to accurately predict and effectively treat those who develop long Covid.

Operation Warp Speed Needed Again

Operation Warp Speed, under the Trump administration, produced three Covid-19 vaccines in record time. When President Trump promised effective vaccines to the new coronavirus in less than a year, liberals and the media mocked him. Yet he delivered. Now, the very same people are calling for another Operation Warp Speed to boost Covid therapies.

Dr. Ezekiel Emanuel, former Biden advisor and developer of ObamaCare, says it’s time to use the same methods to improve our therapeutic response to Covid. Operation Warp Speed also delivered the two monoclonal antibody treatments that were so effective with the Alpha and Delta variants, but less so with Omicron. These same critics of Trump are now criticizing Biden for failing to develop effective therapeutics this winter because they abandoned the program.

Allysia Finley, writing in The Wall Street Journal, says early in the pandemic, the government struggled to persuade drugmakers to invest in vaccines and therapies. Many companies lost money during previous public-health emergencies when treatments they developed turned out not to be needed. “I’m not like a drug company fan, but there’s no question that a lot of them lost a lot of money trying to produce an Ebola vaccine,” said Ron Klain, now White House chief of staff, in February 2020.

Operation Warp Speed shifted the financial risk to government by placing orders for vaccines and therapies before they were authorized by the Food and Drug Administration (FDA) or even shown to be effective. This encouraged pharmaceutical companies to expand manufacturing capacity so vaccines and therapies were ready to be distributed once they had the FDA’s green light.

Three Operation Warp Speed leaders explained the strategy in a September, 2020 commentary for the New England Journal of Medicine. “Predicting drug performance in a new disease is difficult,” Moncef Slaoui, Shannon E. Greene and Janet Woodcock wrote. “Many candidates may fail to demonstrate efficacy or have safety problems. It’s necessary, however, to take a financial risk early to scale up manufacturing in order to have drug supplies on hand if the results are positive. If we wait for clinical trial readouts before initiating large-scale manufacturing, developing an adequate supply could take months or years.”

In July 2020, Operation Warp Speed announced a $450 million manufacturing and supply agreement with Regeneron for up to 300,000 doses of its experimental monoclonal antibody. A few months later, it ordered 300,000 doses of Eli Lilly’s experimental antibody. The FDA granted Emergency Use Authorization (EUA) to both treatments in November, 2020. Supply of both monoclonals exceeded demand last winter because many people were unaware of the treatments. Still, during the final two months of the Trump presidency, Operation Warp Speed ordered another 1.25 million doses of Regeneron’s and 650,000 of Eli Lilly’s antibody treatments, leaving the Biden administration well supplied.

However, in an effort to dismiss “all things Trump”, the Biden team dismissed Mr. Slaoui, announced they were “phasing in a new structure,” and retired the Operation Warp Speed name. Cases and hospitalizations fell as vaccines rolled out. President Biden prematurely declared success last Fourth of July and failed to prepare for another wave by stockpiling treatments and investing in new ones.

When the Delta variant slammed the South in July, GOP governors promoted Regeneron and Eli Lilly monoclonal treatments. Supplies had to be rationed as demand surged. As the Delta wave crested in mid-September, the Pentagon and the Health and Human Services Department ordered 1.4 million more doses of Regeneron’s antibody and 388,000 doses of Eli Lilly’s. Florida Governor Ron DeSantis sought to circumvent the feds by ordering a monoclonal antibody treatment from GlaxoSmithKline and Vir. The antibody binds to a target on Covid-19 that is shared with the SARS virus, making it more difficult for variants to evade. It was authorized by the FDA in May, but the Biden administration then declined to add it to its meager treatment arsenal. Finley says this was a colossal mistake, since it was the only monoclonal treatment for infected patients that turned out to be effective against the Omicron variant. It is hard to escape the conclusion that political rivalry influenced this decision.

Why did the new administration abandon the successful Operation Warp Speed playbook? Ms. Finley says, “Most likely because progressives loathe pharmaceutical companies. Recall how congressional Democrats attacked Mr. Slaoui, a former GSK executive, without evidence, accusing him of profiting off his public service. Or maybe the Biden team believed their own cynical 2020 campaign line that Operation Warp Speed “lacks sound leadership, global vision, or a strategy.”

Asked by New York Times columnist Ezra Klein last week whether the government should adopt OWS’s strategy for other technologies, Mr. Klain replied: “I think we have to be careful about the level of government intervention in the economy and make sure that we’re not putting our judgment in the place of private-sector thoughts and consumer demand and whatnot. I think vaccines are a very, very special case, a public good we wanted everyone to get.”

Ms. Finley says, “He’s right, but life-saving Covid-19 therapies are also a special case. At the same time, the Biden administration wants to spend hundreds of billions of dollars intervening in the economy to support green energy technologies that consumers largely don’t want and are unlikely to do much public good.”